COVID-19-related myocarditis and cholinergic anti-inflammatory pathways

Coronavirus disease-2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2, is currently in a pandemic outbreak and has become a global health issue. In addition to the primarily involvement of the respiratory system, myocarditis is considered an important and fatal lesion in pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Weike, Liu, Zhendong, Li, Yue-Chun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hellenic Society of Cardiology. Publishing services by Elsevier B.V. 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7722500/
https://www.ncbi.nlm.nih.gov/pubmed/33301863
http://dx.doi.org/10.1016/j.hjc.2020.12.004
Descripción
Sumario:Coronavirus disease-2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2, is currently in a pandemic outbreak and has become a global health issue. In addition to the primarily involvement of the respiratory system, myocarditis is considered an important and fatal lesion in patients with COVID-19. However, effective therapeutic methods are currently lacking. The cholinergic anti-inflammatory pathway (CAP) has been demonstrated to suppress pro-inflammatory cytokine production and control inflammation in sepsis and other medical conditions. Therefore, the CAP may be a potential and effective therapeutic method for COVID-19-related myocarditis. This article reviews the relationship between COVID-19-related myocarditis and the CAP and discusses the CAP as a potential therapeutic modality in the treatment of COVID-19-related myocarditis.

Ejemplares similares